{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:29:09Z","timestamp":1793276949803,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011747","name":"Novo Nordisk Foundation Center for Basic Metabolic Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Foundation","doi-asserted-by":"publisher","award":["NNF23SA0084103"],"award-info":[{"award-number":["NNF23SA0084103"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Nutrition"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.tjnut.2026.101684","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T06:10:55Z","timestamp":1781935855000},"page":"101684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Avoiding Malnutrition in the Era of Glucagon-Like Peptide-1 Medications: Emerging Evidence and Opportunities for Integrated Nutrition Care"],"prefix":"10.1016","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-312X","authenticated-orcid":false,"given":"Paola","family":"Mogna-Pel\u00e1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Guasch-Ferr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.tjnut.2026.101684_bib1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/13543776.2020.1811851","article-title":"GLP-1R agonists for the treatment of obesity: a patent review (2015-present), Expert Opin","volume":"30","author":"Liu","year":"2020","journal-title":"Ther. Pat."},{"key":"10.1016\/j.tjnut.2026.101684_bib2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2022.07.017","article-title":"Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: recommendations from a Eastern and Southern Europe diabetes expert group","volume":"365","author":"Janez","year":"2022","journal-title":"Int. J. Cardiol."},{"issue":"6","key":"10.1016\/j.tjnut.2026.101684_bib3","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"issue":"21","key":"10.1016\/j.tjnut.2026.101684_bib4","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tjnut.2026.101684_bib5","doi-asserted-by":"crossref","DOI":"10.1155\/jobe\/9919810","article-title":"Harnessing GLP-1 receptor agonists for obesity treatment: prospects and obstacles on the horizon","volume":"2025","author":"Abdelrahman","year":"2025","journal-title":"J. Obes."},{"issue":"11","key":"10.1016\/j.tjnut.2026.101684_bib6","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.3390\/nu17111934","article-title":"Unintended consequences of obesity pharmacotherapy: A nutritional approach to ensuring better patient outcomes","volume":"17","author":"Al-Najim","year":"2025","journal-title":"Nutrients"},{"issue":"21","key":"10.1016\/j.tjnut.2026.101684_bib7","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.3390\/nu17213318","article-title":"Exploring dietary intake in adults with type 2 diabetes using GLP-1 receptor agonists: A cross-sectional analysis","volume":"17","author":"Ponzo","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.tjnut.2026.101684_bib8","article-title":"Dietary supplement considerations during glucagon-like Peptide-1 receptor agonist treatment: A narrative review","volume":"16","author":"Johnson","year":"2025","journal-title":"Obes. Pillars."},{"key":"10.1016\/j.tjnut.2026.101684_bib9","article-title":"Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: a retrospective observational study","volume":"15","author":"Scott Butsch","year":"2025","journal-title":"Obes. Pillars."},{"issue":"11","key":"10.1016\/j.tjnut.2026.101684_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.cdnut.2025.107587","article-title":"GLP-1 receptor agonists \u2013 good for body weight, bad for micronutrient status?","volume":"9","author":"Kerlikowsky","year":"2025","journal-title":"Curr. Dev. Nutr."},{"key":"10.1016\/j.tjnut.2026.101684_bib11","article-title":"Dietary intake by patients taking GLP-1 and dual GIP\/GLP-1 receptor agonists: A narrative review and discussion of research needs","volume":"11","author":"Christensen","year":"2024","journal-title":"Obes. Pillars."},{"issue":"1","key":"10.1016\/j.tjnut.2026.101684_bib12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am. J. Clin. Nutr."},{"issue":"2","key":"10.1016\/j.tjnut.2026.101684_bib13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.14255","article-title":"Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes","volume":"23","author":"Gibbons","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.tjnut.2026.101684_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2025.1566498","article-title":"Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study","volume":"12","author":"Johnson","year":"2025","journal-title":"Front Nutr"},{"issue":"5","key":"10.1016\/j.tjnut.2026.101684_bib15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000544023","article-title":"Dermatologic implications of glucagon-like Peptide-1 receptor agonist medications","volume":"11","author":"Burke","year":"2025","journal-title":"Skin Appendage Disord"},{"key":"10.1016\/j.tjnut.2026.101684_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.tjnut.2026.101684_bib17","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.2147\/DDDT.S531778","article-title":"Semaglutide therapy and accelerated sarcopenia in older adults with type 2 diabetes: A 24-month retrospective cohort study","volume":"19","author":"Ren","year":"2025","journal-title":"Drug Des. Devel. Ther."},{"issue":"5","key":"10.1016\/j.tjnut.2026.101684_bib18","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1093\/ejendo\/lvaf223","article-title":"Glucagon-like peptide-1 receptor agonists and muscle health: potential role in sarcopenia prevention and treatment","volume":"193","author":"Gonz\u00e1lez-Luis","year":"2025","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.tjnut.2026.101684_bib19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3390\/nu17010132","article-title":"The etiology of reduced muscle mass with surgical and pharmacological weight loss and the identification of potential countermeasures","volume":"17","author":"Faria","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.tjnut.2026.101684_bib20","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.2147\/DMSO.S494919","article-title":"Dietary recommendations for the management of gastrointestinal symptoms in patients treated with GLP-1 receptor agonist","volume":"17","author":"Gentinetta","year":"2024","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.tjnut.2026.101684_bib21","article-title":"Ozempic is shrinking appetites. Restaurants are shrinking the food","author":"Krueger","year":"2025","journal-title":"The New York Times [Internet]"},{"key":"10.1016\/j.tjnut.2026.101684_bib22","article-title":"The Ozempic Effect: How Weight-Loss Drugs Are Rewriting the Rules of Dining Out","author":"Provencher","year":"2025","journal-title":"Food & Wine [Internet]"},{"issue":"1","key":"10.1016\/j.tjnut.2026.101684_bib23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s13668-025-00649-w","article-title":"Impact of GLP- 1 receptor agonist therapy in patients high risk for sarcopenia","volume":"14","author":"Memel","year":"2025","journal-title":"Curr. Nutr. Rep."},{"key":"10.1016\/j.tjnut.2026.101684_bib24","article-title":"Malnutrition is common in patients utilizing glucagon-like Peptide-1 agonists prior to total joint arthroplasty, Arthroplast","volume":"35","author":"Jodoin","year":"2025","journal-title":"Today"},{"issue":"4","key":"10.1016\/j.tjnut.2026.101684_bib25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.4093\/dmj.2025.0242","article-title":"Exploring the side effects of GLP-1 receptor agonist: to ensure its optimal positioning","volume":"49","author":"Kim","year":"2025","journal-title":"Diabetes Metab. J."},{"issue":"Suppl 4","key":"10.1016\/j.tjnut.2026.101684_bib26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26","author":"Neeland","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"10.1016\/j.tjnut.2026.101684_bib27","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/oby.24067","article-title":"Nutritional considerations with antiobesity medications","volume":"32","author":"Almandoz","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.tjnut.2026.101684_bib28","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/DMSO.S387116","article-title":"The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: systematic review of randomized controlled trials","volume":"16","author":"Aldawsari","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"Suppl 4","key":"10.1016\/j.tjnut.2026.101684_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.15829","article-title":"Opportunities to optimize lifestyle interventions in combination with glucagon-like peptide-1-based therapy","volume":"26","author":"Dash","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.tjnut.2026.101684_bib30","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s13679-025-00667-3","article-title":"A multidisciplinary perspective on semaglutide treatment and medical nutrition therapy in obesity management","volume":"14","author":"Barrea","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.tjnut.2026.101684_bib31","article-title":"Application of nutrition interventions with GLP-1 based therapies: A narrative review of the challenges and solutions","volume":"16","author":"Fitch","year":"2025","journal-title":"Obes. Pillars."}],"container-title":["The Journal of Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022316626003330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022316626003330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:36:06Z","timestamp":1786480566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022316626003330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022316626003330"],"URL":"https:\/\/doi.org\/10.1016\/j.tjnut.2026.101684","relation":{},"ISSN":["0022-3166"],"issn-type":[{"value":"0022-3166","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avoiding Malnutrition in the Era of Glucagon-Like Peptide-1 Medications: Emerging Evidence and Opportunities for Integrated Nutrition Care","name":"articletitle","label":"Article Title"},{"value":"The Journal of Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjnut.2026.101684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Nutrition.","name":"copyright","label":"Copyright"}],"article-number":"101684"}}